Alliances
Filter News
Found 55,742 articles
-
CosmosID Announces Collaboration with Resilient Biotics for Advanced Microbiome Exploration of the Respiratory Tract
3/21/2024
CosmosID, a renowned microbiome analytics company, is thrilled to announce a groundbreaking collaboration with Resilient Biotics, a leading microbiome platform company with a pipeline of products for maintaining respiratory tract health.
-
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
3/21/2024
Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine),
-
Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis
3/21/2024
Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women's Hospital, Champalimaud Foundation and Ohio State University (OSU).
-
Remission Medical Partners with Sentara Health to Expand Access to Rheumatology Care
3/20/2024
Remission Medical announced a partnership with Sentara Health to increase access to Rheumatology care for adult patients.
-
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
3/20/2024
Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.
-
Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Greater China and key Asian countries
3/20/2024
Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries.
-
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
3/20/2024
Onymos, developer of the world's first Features-as-a-Service platform, and Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm"), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership.
-
Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
3/20/2024
Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
-
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
3/20/2024
Entera Bio Ltd. announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist developed by OPKO Health, Inc. (Nasdaq: “OPK”, or “OPKO”) with Entera’s proprietary N-Tab™ technology.
-
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
3/20/2024
Tonix Pharmaceuticals Holding Corp. today announced it has selected two contract manufacturing organizations (CMOs), one of which is Almac Pharma Services, a member of the privately owned Almac Group, as dual supply sources for the potential launch and commercialization of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in the U.S.
-
SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America
3/20/2024
SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an important drug for cancer patients to Latin America.
-
Koneksa Announces Merck Joins Data Syndication Partnership Program Around Parkinson’s Digital Biomarkers Observational Study
3/20/2024
Koneksa announced that Merck has joined its Data Syndication Partnership program for the LEARNS observational study, which seeks to develop digital biomarkers in neurodegenerative disorders from smart phone-based assessments and wearable technologies.
-
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
3/20/2024
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today a groundbreaking exclusive worldwide license agreement (the "License Agreement") with Aexon Labs, Inc., a U.S.-based biotech firm ("Aexon").
-
Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever
3/20/2024
Primmune Therapeutics today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.
-
Partnership agreement between Croda and AAHI to drive innovation in vaccine development
3/19/2024
Croda International Plc and The Access to Advanced Health Institute are pleased to announce the signing of a partnership agreement around innovation and development of adjuvant formulations, under which Croda and AAHI will leverage their combined expertise to make novel vaccine adjuvant formulations globally accessible, thereby advancing next generation, robust and durable vaccines.
-
Unravel Announces Initiation of RVL001 Clinical Trial Material Manufacturing to Support Upcoming US and International Clinical Trials in Rett Syndrome
3/19/2024
Unravel Biosciences, Inc., ("Unravel") today announced a manufacturing and development partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture RVL001 clinical trial material for use in upcoming Rett syndrome clinical trials in the US and Colombia.
-
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
3/19/2024
ClearPoint Neuro, Inc. today congratulates its partner PTC Therapeutics on completion of its BLA submission to the U.S. Food and Drug Administration (FDA) for the approval of Upstaza.
-
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
3/19/2024
Nascent Biotech, Inc. and HypoSpray Pharma announced today a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab.
-
Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform
3/19/2024
Aegis Life receives a program-related investment of $4.45M from the Bill & Melinda Gates Foundation.
-
ATCC Announces Award from the National Cancer Institute to Provide Biospecimen Processing Services and Assays for Cancer Research
3/19/2024
ATCC will continue to support the National Cancer Institute's (NCI) mission to prevent cancer and the Division of Cancer Epidemiology and Genetics (DCEG) Biospecimen Activity and Assay Support (BAAS) program.